DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x4rmpx/hepatitis_c) has announced the addition of the "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" report to their offering.
Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.
Key Topics Covered
- Executive Summary
- Hepatitis C Drugs - Market & Forecast
- Hepatitis C - Approved Drugs Sales & Forecast
- Hepatitis C - Pipeline Drugs Sales Forecast
- Hepatitis C - Deals & Acquisitions
- Hepatitis C - Company Wise Clinical Trials Analysis
- Bristol-Myers Squibb (BMS)
- Gilead Sciences
- Merck & Co.
- Tibotec/Janssen Therapeutics
For more information visit http://www.researchandmarkets.com/research/x4rmpx/hepatitis_c